At ASGCT, the company will share data showing that its RNA achieves higher, more durable protein expression compared to other ...

The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene ...

For the second year in a row, GEN spoke with David Barrett, JD, who has been the CEO of ASGCT since 2016. In this interview, we discuss his perspective on the event, if there is anything new that ...

Enein, MD, PhD, for a measurement-driven approach that advances cell therapy translation, from high-dimensional analytics to ...